Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
eNrlWE1z2jAQvfMrGA69CWMDAVpDpqVJy0wypSRMO70wQl5AVEiOPoD011fG0JCOKa3Ah7YXxkjy27X09u2uwsv1ghWXIBUVvF3yy5VSETgREeXTdml4f42apctOIZzjJX5aFth1Zd8vFQnDSrVLyWx5DJir8ufbm7dg3wdZ6hSKoRjPgehn64ymrPweq9ktjpM1xXApaFRcgJ6JqF2Kjd6MFkOlpfWisxLyq4oxgdDbjuzPzke1/fHQS8B+A9UokDeYTzNBgTthEiMlcN3FGqZCPmZCxzLyR0GreeG3mk5GqBqAEkYS6GM960uxpBFEmbYmmClwMjJZRXcglwx0YiQT3JuThXICx3O8HsBDL9vp13a2q9caVZDfaFX9RhA0avXWhZMpubdV2fSxH+HFo2q1VbnwAw+4FwGhCcsRDypBgCq1Wt2LiKdggSKDghriYgmLsQS0mbdjRDAGU0ARIIbRDBsNyP4ISfVmUGFuH2IhtX1AEiZGbddGsMDcPkYIEwIKxdKGDtkhqdi6glmCooFYYkn64EiZfmKc5UQWqrrPiZ+THQkPR0kZURUz/Fieq9h1q7DEdhqklaf8PiT5gntpBZPZPfsJnxvGvD/0eriVs5w8TtSyK4ylYLaqXQ9cN6IrbHCsD5+omxDr9ZaLFNT5YL8Jnp2E+mbMKHFVWquFBpQeDnqHhfY/0Kg3WMFQ5idSnyiPxEqdX/z2yZaT95uDYUcKinrdOba/WGYfyMdXRooYPCuLVJ2idj0+EafqnA2WbKhdqPzrUbKpWgXBDA7UrchRiW147Mrs3AIwv+BOJzJB313du7L2owH5eLf5mwlNo/YPvrmlqTxyn42RY46napI4X6k3W9XaC7yIX+0aorZj85OC/rL3mZBR0GzUmlW3zsfIbAWcaR2rl563Wq3KM6zSKC1P5F+XOC8zD+Ych2Oz1BPX8usZcynm0uI2zVA5uT5OS48/Y5errBwr905tYbbvb1ulTBtaGjjhLNIMlFue6F2dP/U89S+5ud1/JoD5mdn0GlhbFcur2DTj7LRxUrKz58qvpRWID5MJPXCZd5CXoZdeJHYKoZdcInYK3wF8A9fK
chYafdNVjusVUeuu